Clinical Trial Update: The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the immunogenicity and safety of NBP608 in healthy children aged 12 months to 12 years for Varicella has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• NBP608

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Varicella | Phase 2 | Status: COMPLETED